Press release
Primary Sclerosing Cholangitis Pipeline Outlook Report 2025: Emerging Therapies and Innovation Trends by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Primary Sclerosing Cholangitis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Primary Sclerosing Cholangitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report
* On 24 October 2025, LISCure Biosciences conducted a study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis. Part 1 will evaluate safety and tolerability of 2 pre-selected dose level of LB-P8 (low-dose [1 times 10^10 CFU/capsule] and high dose [1 times 10^11 CFU/capsule]) in adult patients with PSC. Part 1 plans to enroll a maximum number of 12 patients based on a "3+3" study design.
* On 23 October 2025, HighTide Biopharma Pty Ltd conducted a study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.
* DelveInsight's Primary Sclerosing Cholangitis pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Primary Sclerosing Cholangitis treatment.
* The leading Primary Sclerosing Cholangitis Companies such as Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
* Promising Primary Sclerosing Cholangitis Pipeline Therapies such as Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.
Discover how the Primary Sclerosing Cholangitis Treatment paradigm is evolving. Access DelveInsight's in-depth Primary Sclerosing Cholangitis Pipeline Analysis for a closer look at promising breakthroughs @ Primary Sclerosing Cholangitis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Sclerosing Cholangitis Emerging Drugs Profile
* GS-9674: Gilead Sciences
GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.
* IMU-838: Immunic
IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn's Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.
The Primary Sclerosing Cholangitis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
* Primary Sclerosing Cholangitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market
Explore groundbreaking therapies and clinical trials in the Primary Sclerosing Cholangitis Pipeline. Access DelveInsight's detailed report now! @ New Primary Sclerosing Cholangitis Drugs [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Sclerosing Cholangitis Companies
Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Primary Sclerosing Cholangitis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Primary Sclerosing Cholangitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Primary Sclerosing Cholangitis Pipeline Report
* Coverage- Global
* Primary Sclerosing Cholangitis Companies- Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
* Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.
* Primary Sclerosing Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Primary Sclerosing Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Primary Sclerosing Cholangitis Drug development? Find out in DelveInsight's exclusive Primary Sclerosing Cholangitis Pipeline Report-access it now! @ Primary Sclerosing Cholangitis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Primary Sclerosing Cholangitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Primary Sclerosing Cholangitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GS-9674: Gilead Sciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IMU-838: Immunic
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* SCO-240: SCOHIA PHARMA
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* MORF 627: Morphic Therapeutic
* Drug profiles in the detailed report.....
* Inactive Products
* Primary Sclerosing Cholangitis Key Companies
* Primary Sclerosing Cholangitis Key Products
* Primary Sclerosing Cholangitis- Unmet Needs
* Primary Sclerosing Cholangitis- Market Drivers and Barriers
* Primary Sclerosing Cholangitis- Future Perspectives and Conclusion
* Primary Sclerosing Cholangitis Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-pipeline-outlook-report-2025-emerging-therapies-and-innovation-trends-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Pipeline Outlook Report 2025: Emerging Therapies and Innovation Trends by DelveInsight here
News-ID: 4245737 • Views: …
More Releases from ABNewswire
Systemic Juvenile Idiopathic Arthritis Market Analysis 2034 - Competitive Landsc …
Systemic Juvenile Idiopathic Arthritis Companies are Chugai Pharmaceutical, AstraZeneca, Pfizer, Incyte Corporation Novartis, Roche, Genentech, AbbVie, Pfizer, Eli Lilly and Company, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., UCB, Sanofi, and others.
DelveInsight's "Systemic Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Systemic Juvenile Idiopathic Arthritis, historical and forecasted epidemiology as well as the Systemic Juvenile Idiopathic Arthritis market trends in the…
Global Bone Graft and Substitutes Market Set for Strong Growth to Reach USD 5.96 …
Increasing incidence of bone-related disorders, trauma cases, and rising demand from the dental and orthopedic sectors to drive steady growth across global regions.
DelveInsight's "Bone Graft and Substitutes Market Insights, Competitive Landscape, and Market Forecast - 2032" report delivers a comprehensive analysis of the Bone Graft and Substitutes market globally.
The global Bone Graft and Substitutes Market, segmented by source, product type, application, end-user, and geography, is poised for consistent growth through…
Systemic Lupus Erythematosus Pipeline Outlook Report 2025: Emerging Therapies an …
DelveInsight's, "Systemic Lupus Erythematosus Pipeline Insights 2025" report provides comprehensive insights about 120+ companies and 140+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape. It covers the Systemic Lupus Erythematosus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Lupus Erythematosus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's…
Multiple Sclerosis Pipeline Outlook Report 2025: Emerging Therapies and Innovati …
DelveInsight's "Multiple Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
